The EMA validation de-risks the European regulatory pathway and sets up a binary catalyst window around the November 28, 2026 PDUFA date for the FDA decision. Monitor for any EMA CHMP opinion timeline updates and potential partnership or licensing announcements for ex-US/Canada territories as the regulatory process advances.
Price Chart
Executive Summary
PolyPid announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for D-PLEX, the company's lead product candidate for preventing post-abdominal surgery infections. The validation confirms the application is complete and initiates formal EMA review, while the FDA concurrently reviews the NDA under Priority Review with a PDUFA goal date of November 28, 2026. This is a positive regulatory milestone that advances D-PLEX toward potential approval in both the US and EU markets.
Key Facts
- EMA validated PolyPid's MAA for D-PLEX on October 1, 2026, confirming the application is complete and initiating formal review by the CHMP.
- MAA was submitted on September 14, 2026 under the Centralized Procedure on the basis of therapeutic innovation.
- If approved, D-PLEX would receive a single marketing authorization valid throughout all EU member states.
- FDA NDA for D-PLEX is under Priority Review with a PDUFA goal date of November 28, 2026.
- The MAA is supported by the Phase 3 SHIELD II trial which met its primary endpoint and showed a 60% relative risk reduction in SSIs (p=0.0013).
- PolyPid retains commercial rights to D-PLEX outside the US and Canada; Azurity Pharmaceuticals is the partner for US/Canada.
Financial Impact
No financial figures provided in the filing. The European SSI market is described as 'significant' by management, but no dollar amounts or revenue projections are stated.
Risk Factors
- Regulatory approval is not guaranteed; the EMA or FDA may request additional data or deny the application.
- Commercialization depends on successful pricing and reimbursement negotiations in EU member states.
- The company is pre-revenue and relies on financing to fund operations and commercialization efforts.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-105492 |
| Document: ea0307316-6k_polypid.htm | 0001213900-26-105492 |
| Document: 0001213900-26-105492-index-headers.html | 0001213900-26-105492 |
| Document: 0001213900-26-105492-index.html | 0001213900-26-105492 |
| Document: 0001213900-26-105492.txt | 0001213900-26-105492 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $4.90 | awaiting T+60 | — | $5.29 (+7.96%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.29 (+10.67%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.29 (+29.66%) |
Jul 21, 2026 14w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.29 (+41.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers